Chugai Seiyaku Kabushiki Kaisha

Other

Shinshu University

National Hospital Organization

Tadamitsu Kishimoto

Sugiyama, Haruo

Kishimoto, Tadamitsu

Mayumi, Tadanori

Yoshiyuki Ohsugi

Masahiko Mihara

Takashi Mori

Minoru Shindo

Takashi Matsuno

Yoichiro Moriya

Yasuhiro Yamashita

Yasushi Murakami

Yoshimitsu Iida

Sakae Takaku

Shun-ichi Hata

Koji Mizuno

Toshichika Ogasawara

Teizo Shinozaki

Kazuo Igusa

Shigeyuki Kataoka

Kiyoshige Wakabayashi

Yasuho Nishii

Nobuhiro Ohi

Yasuhisa Takeda

Masaji Okada

Masayoshi Ono

Mitsuru Tanemura

Akira Okazaki

Atsushi Izawa

Masafumi Takahashi

Toshiaki Nakano

Akiko Ariga

The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

Methods for suppressing acute rejection of a heart transplant

There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor. The pharmaceutical composition for treatment of chronic rheumatoid arthritis or synovial cell growth inhibitor contains an IL-6 antagonist, such as IL-6 antibody or IL-6R antibody, as an effective component.

Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component

Chronic rheumatoid arthritis therapy containing IL-6 antagonist as

A compound of the formula ##STR1## wherein R.sub.1 is a hydrogen atom or a lower alkyl group which may be substituted with hydroxy, lower alkyl or di-lower alkylamino; R.sub.2 is a hydrogen atom, an amino group or a lower alkylamino group; and R.sub.3 is a lower alkyl group, and a non-toxic salt thereof, and a process for preparing the same are disclosed. The compound and the salts thereof exhibit anti-allergic effects by the two different mechanisms and are expected to be useful as drugs for treating allergic diseases such as asthma, pollen allergy, atopic dermatitis and the like.

Pyridine derivatives and their use as anti-allergic agents

A terephthalic acid monoamide derivative of the formula: ##STR1## (wherein R is a straight- or branched-chain lower alkyl group; R' and R' may be the same or different, and represent a hydrogen atom, or a straight- or branched-chain lower alkyl group) or pharmaceutically acceptable salts thereof are disclosed. A process for preparing such terephthalic acid monoamide derivative or its salts, as well as an anti-allergic agent containing such derivative or its salts as an effective ingredient are also disclosed.

Terephthalic acid monoamide derivatives, process for preparing the same,

An aminobenzoic acid derivative represented by the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are defined hereinbelow, which has excellent activity for improving liver function and for potentiating and normalizing immunity; a process for preparing the same; and a pharmaceutical composition containing the same are disclosed.

Novel aminobenzoic acid derivatives, process for preparing the same and

Growing community of inventors

Tokyo, Japan

Yoshiyuki Ohsugi